Abstract
Immunotherapies such as immune checkpoint blockade benefit only a portion of patients with head and neck squamous cell carcinoma. The multidisciplinary field of nanomedicine is emerging as a promising strategy to achieve maximal anti-tumor effect in cancer immunotherapy and to turn non-responders into responders. Various methods have been developed to deliver therapeutic agents that can overcome bio-barriers, improve therapeutic delivery into the tumor and lymphoid tissues and reduce adverse effects in normal tissues. Additional modification strategies also have been employed to improve targeting and boost cytotoxic T cell-based immune responses. Here, we review the state-of-the-art use of nanotechnologies in the laboratory, in advanced preclinical phases as well as those running through clinical trials assessing their advantages and challenges.
Original language | English (US) |
---|---|
Pages (from-to) | 2506-2517 |
Number of pages | 12 |
Journal | International Journal of Biological Sciences |
Volume | 16 |
Issue number | 14 |
DOIs | |
State | Published - Jul 19 2020 |
Keywords
- Cancer immunotherapy
- Drug delivery
- Head and neck squamous cell carcinoma, human papillomavirus
- Nanotherapeutics
- Nanovaccine
ASJC Scopus subject areas
- Ecology, Evolution, Behavior and Systematics
- Applied Microbiology and Biotechnology
- Molecular Biology
- Developmental Biology
- Cell Biology